Norway pharmacy online: Kjøp av viagra uten resept i Norge på nett.

Jeg kan anbefale en god måte for å øke potens - Cialis. Fungerer mye bedre kjøp levitra Alltid interessant, disse pillene og andre ting i Generelle virkelig har helse til å handle.

Microsoft word - 53-13 patient group directions.doc

Hastings and Rother CCG
Governing Body meeting
Date of meeting: 21 March 2013

Item Number: 53/13
Title of report:
Patient Group Directions (PGDs)
Adoption of the existing PGDs by East Sussex Clinical Commissioning Groups (CCGs)
Recommendation:
It is recommended that the Governing Body:
approve the adoption of all existing PGDs in use within the PCT area direct that a CCG PGD development and authorisation group be established. Summary:
There are PGDs currently in use within the PCTs and these are authorised by the Head
of Quality and Safety (East). As part of transition, legislation is being amended by the
Medicines and Healthcare products Regulatory Agency (MHRA) and Department of
Health to:
(i) enable Clinical Commissioning Groups and Local Authorities to authorise PGDs from April 2013; and (ii) to ensure that existing PGDs with an expiry date after 31 March 2013 will continue to be legal until the PGD either expires or is replaced. Guidance requires that CCG Governing Bodies approve the adoption of all existing
PGDs and direct that a CCG PGD development and authorisation group (separately or
jointly with other CCGs or Local Authority) be established. This should be formally
minuted.
There are 17 PGDs for practice nurses, 3 for the Hastings and Rother MSK service, and
1 for the Apollo Centre in Eastbourne.
Board Sponsor:
Dr Rob McNeilly, CCG board GP
Author:
Date of report:
Richard Partington, CCG Medicines Management Advisor Review by other committees:
None, this has not been required for this paper.
Health impact:
To enable the continuation of practice under PGD in delivering services to patients.
Financial implications:
There are no financial implications.
Hastings and Rother Clinical Commissioning Group Legal or compliance implications:
All PGDs will cease to be valid beyond 1st April 2013 if not formally accepted by CCG
Governing Bodies.
Link to key objective and/or assurance framework risk:
Ensuring robust governance arrangements
Patient and public engagement:
None, this has not been required for this paper as it is the approval of existing PGDs as
part of the transfer arrangements to new receiving organisations.
Equality impact assessment completed:
None, this has not been required for this paper as it is the approval of existing PGDs as
part of the transfer arrangements to new receiving organisations.
Hastings and Rother Clinical Commissioning Group Patient Group Directions (PGDs)
Executive summary
1. PGDs are currently authorised jointly by Hastings and Rother and East Sussex Downs
2. Legislation is being amended by the Medicines and Healthcare products Regulatory Agency (MHRA) and Department of Health to: 2.1 enable Clinical Commissioning Groups and Local Authorities to authorise PGDs 2.2 ensure that existing PGDs with an expiry date after 31 March 2013 will continue to be legal until the PGD either expires or is replaced. 3. Whilst this legislation has not yet been finalised, current guidance is that all organisations who wish to continue to use existing PGDs must document in their board minutes that they accept current PGDs to transfer over to CCGs, and that they will form a PGD development and authorisation group.
Existing Patient Group Directions

4. These changes are consequential to the Health and Social Care Act 2012, and will
enable the continued use of PGDs in new health system organisational structures. 5. The following PGDs are currently authorised in Hastings and Rother and East Sussex Downs and Weald PCTs (see tables below for details): • 17 for practice nurses • 3 for Hastings and Rother MSK service • 1 for Apollo Centre in Eastbourne • 1 for community pharmacy (emergency contraception) – this transfers to Public PGDs for practice nurses
PGD number
Expiry date
Hastings and Rother Clinical Commissioning Group H&R MSK service PGDs
PGD number
Expiry date
methylprednisolone 40mg with lidocaine 10mg/ml
EHS Apollo Centre PGD
PGD number
Expiry date
6. Hastings and Rother CCG Governing Body are required to formally document • all 17 practice nurse PGDs • 3 MSK service PGDs 7. Eastbourne, Hailsham and Seaford CCG Governing Body are required to formally • all 17 practice nurse PGDs • the 1 Apollo Centre PGD
8. High Weald Lewes Havens CCG Governing Body are required to formally document

PGD Development and Authorisation Group

9. The authorisation group can be developed separately by each CCG or jointly with any
other CCGs or LAs. It is suggested (by the medicines management team) that this group should operate jointly across Hastings and Rother and Eastbourne and Hailsham CCGs, with the potential to also include High Weald Lewes Havens CCG subject to further discussion regarding the practicalities of implementation. The medicines management team also recommend that the group, when formed, should consist of, as a minimum: • a GP Prescribing Lead • a Medicines Management Advisor • a practice nurse lead • a CCG senior governance officer.
Conclusion

10. This is a legally required process to allow the use of PGDs to continue after 1st April Hastings and Rother Clinical Commissioning Group Recommendation
11.It is recommended that the Governing Body: • approve the adoption of all existing PGDs in use within the PCT area direct that a CCG PGD development and authorisation group be established to develop, review, and authorise PGDs, and that this is stated in the Governing Body minutes agree that the relevant Governing Body meeting minutes state formal acceptance of the relevant PGDs detailed above, as required for each CCG. Hastings and Rother Clinical Commissioning Group

Source: http://www.hastingsandrotherccg.nhs.uk/website/XHRCCG/files/53-13_Patient_Group_Directions.pdf

Patient work up answer key

Pharmacy Case Based Exam I Directions: Review the following Subjective and Objective findings and then, complete the SOAP note by writing an Assessment, Goals, and Plan. Also complete preparepharmacokinetic monitoring forms for each anticonvulsant. Make sure you accuratelycomplete these forms. Weighting of Items: Assessment , Goals, and Plan = 63 points; Monitoring Forms = 25 points

lisboa.adagio4.eu

Terça-feira, 20 de Julho de 1999 Número 167/99 I A Esta 1.a série do Diário da República é constituída pelas partes A e B DIÁRIO DA REPÚBLICA Sumario167A Sup 0 S U M Á R I O Supremo Tribunal de Justiça Comissão Nacional de Eleições DIÁRIO DA REPÚBLICA — I SÉRIE-A SUPREMO TRIBUNAL DE JUSTIÇA Procurando regulamentar melhor esta questão — a

Copyright © 2010-2014 Drug Shortages pdf